Worth Venture Partners, LLC Medicenna Therapeutics Corp. Transaction History

Worth Venture Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.44 - $0.82 $15,457 - $28,806	35,130 Added 3.33%	1,088,938 $522,000
Q1 2023 May 15, 2023	SELL	$0.5 - $0.78 $8,565 - $13,361	-17,130 Reduced 1.6%	1,053,808 $663,000
Q4 2022 Feb 14, 2023	BUY	$0.4 - $0.68 $42,854 - $72,853	107,137 Added 11.12%	1,070,938 $492,000
Q3 2022 Nov 14, 2022	BUY	$0.83 - $1.78 $325,618 - $698,315	392,312 Added 68.65%	963,801 $799,000
Q1 2022 May 16, 2022	BUY	$1.26 - $1.92 $73,584 - $112,128	58,400 Added 11.38%	571,489 $727,000
Q4 2021 Feb 14, 2022	BUY	$1.53 - $2.85 $456,030 - $849,468	298,059 Added 138.61%	513,089 $837,000
Q2 2021 Aug 16, 2021	BUY	$2.97 - $4.28 $50,876 - $73,316	17,130 Added 8.66%	215,030 $647,000
Q1 2021 May 17, 2021	BUY	$3.5 - $4.56 $692,650 - $902,423	197,900 New	197,900 $807,000

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Worth Venture Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Worth Venture Partners, LLC with notifications on news.